PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that did not get better with standard treatment or came back after improving.
- Your kidney function is at least 30% of normal (measured by creatinine clearance).
- Your blood counts are within a safe range (lymphocytes, neutrophils, platelets, hemoglobin) without needing transfusions or certain growth factors within 7 days before screening.
- You have not had certain B-cell therapies (like rituximab) in the last 6 months, unless your B cells have returned.
- You do not have active hepatitis B, C, HIV, or syphilis, and you have not had cancer in the last 5 years (except for a few specific types).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
This trial tests a new drug called IPG11406 for people with active lupus nephritis, a type of kidney inflammation caused by lupus. It aims to see if the drug can help reduce kidney damage and improve symptoms.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a new treatment using immune cells (CAR-NK) designed to target and kill specific cells that may cause IgG4-related disease (IgG4-RD). It is for people whose IgG4-RD has come back or not responded to standard treatments.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.